The Japanese firm has agreed to make a $50 million investment in Dallas-based Taysha in exchange for a 15% stake in the company, plus exclusive options to license two clinical-stage, single-gene therapies for rare genetic diseases.
The option covers TSHA-102, currently the only gene therapy in clinical testing for developmental disorder Rett syndrome, and TSHA-120, a phase 1/2 candidate for the inherited central and peripheral nervous system disorder giant axonal neuropathy (GAN).
